This study tests a drug called maridebart cafraglutide to see if it helps people with heart disease who are also overweight. Cardiovascular disease (CVD) is when the heart or blood vessels have problems. The study compares maridebart cafraglutide to a placebo, which looks like the real drug but has no medicine in it. The goal is to check if this new drug can better reduce heart-related problems and deaths compared to the placebo.

To join, you must be at least 45 years old and have a body mass index (BMI) of 27 or more. You also need to have a history of atherosclerotic cardiovascular disease (ASCVD), like a past heart attack or stroke. Some people cannot join, like those with recent major heart issues or certain diabetes problems.

• The study checks if maridebart cafraglutide can reduce heart problems better than a placebo.
• You need to be 45+ and have a BMI of 27 or more to participate.
• Participants must have a history of heart disease but not recent major heart events.